Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780681 | 0.86 | CHRNB4 (0.41) | DCPSCYP2D6CHRNB4CHRNA3SSTR5 | |
| SCHEMBL5779504 | 0.86 | CHRNB4 (0.41) | DCPSCYP2D6CHRNB4CHRNA3ACHE | |
| SCHEMBL5778455 | 0.86 | CHRNB4 (0.40) | DCPSCYP2D6CHRNB4CHRNA3SSTR5 | |
| SCHEMBL5780296 | 0.85 | CHRNB4 (0.41) | DCPSCYP2D6CHRNB4CHRNA3ACHE | |
| SCHEMBL5780578 | 0.81 | MAOB (0.44) | ACHE | |
| SCHEMBL5781506 | 0.81 | TLR4 (0.45) | CHRNB4CHRNA3ACHEACKR3 | |
| SCHEMBL5784140 | 0.81 | DCPS (0.52) | DCPSCYP2D6CHRNB4CHRNA3SSTR5 | |
| SCHEMBL5780279 | 0.80 | DCPS (0.40) | DCPSCYP2D6 | |
| SCHEMBL5780044 | 0.77 | KCNH2 (0.48) | CHRNB4CHRNA3KCNH2 | |
| SCHEMBL5782945 | 0.77 | PDCD1LG2 (0.41) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | claimed |
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | DCPS 3564/4885CYP2D6 442/4885CHRNB4 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.